Trophic Ulcer, Leprosy, Morbus Hansen
Conditions
Keywords
CM-MSC, Stemcell, trophic ulcer, leprosy, morbus hansen, secretom
Brief summary
Background: Trophic ulcer is one of the complications that arise due to leprosy infection of the skin and includes diseases that trigger permanent disability and reduce the quality of life of the person. The facts in the field that more than 50% of chronic ulcers, especially trophic ulcers due to leprosy fail to heal with usual treatment. Therefore it is important to do a new method in healing trophic ulcers. Stem cell therapy or one of them is conditioned medium mesenchymal stem cell is a promising therapy because of its biological and physiological processes resembling the mechanism of wound healing Method: This research is a clinical trial research "Open Trial". Phase 1 to see the side effects caused by the intervention. Minimum sample size of 20 respondents with trophic ulcers due to leprosy that is difficult to resolve with usual treatment. The main outcome is wound healing in terms of the length and extent of the wound. The secondary outcome is treatment toxicity 4 weeks after administration. Follow-up visits will be scheduled at 2, 4, and 12 weeks post-treatment. If the results confirm safety, feasibility and potential efficacy, large multicenter randomized controlled trials with longer follow-up will begin with a focus on the effectiveness of therapy
Interventions
BIOLOGICALSecretome
The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
Sponsors
Yohanes Firmansyah, dr, MH, MM
Tarumanagara University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Chronic ulcers in Morbus Hansen's patients aged 18-80 years * Not recovering with routine therapy for at least 1 months * Trophic ulcers degrees 2 and 3 * Willing to take part in the study * As well as with the respondent's good health to follow this study.
Exclusion criteria
* Patients who took anticoagulants, * Patients had hypertension * Patients had any staging kidney failure * Patients had a history of blood disorders and pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Wound Size - Length | 4 weeks | Digital measurements of Length carried out using a rule from time to time (1 time per week for 4 weeks) with units in cm |
| Changes in Wound Size - Width | 4 weeks | Digital measurements of Width carried out using a rule from time to time (1 time per week for 4 weeks) with units in cm |
| Changes in Wound Size - Area | 4 weeks | Digital measurements carried out by multiplying the length and width of the wound over time (1 time per week for 4 weeks) in units of cm squares |
Countries
Indonesia
Outcome results
None listed